Penn Medicine News Release

Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin’s Lymphoma

In a pair of clinical trials stretching from Philadelphia to Tokyo, the CAR T cell therapy Kymriah™ demonstrated long-lasting remissions in non-Hodgkin’s lymphoma patients. Results from a global, multi-site trial were presented at the 59th American Society of Hematology Annual Meeting, and results from the single-site study, with follow-up extending past two years, were published in NEJM. Both studies were led by Stephen J. Schuster, MD.

On the News Blog

Penn Medicine In the News

  • Philly-Area Emergency Rooms Adjust to Increase of Opioid Overdose Cases

    December 14, 2017
  • The Most Groundbreaking Cancer Research of 2017

    December 14, 2017
  • A ‘Game Changer’ for Patients with Irregular Heart Rhythm

    December 14, 2017
Share This Page: